Loading
Cisplatin and carboplatin cost a few dollars a dose yet ran short across the US in 2023 because too few makers found them worth producing; a non-profit maker with long-term hospital contracts would keep them on the shelf.
Civica Rx showed that a hospital-owned non-profit can manufacture and stock essential generics under long-term, fixed-price contracts, stabilising supply of sterile injectables. Oncology generics (platinums, fluorouracil, methotrexate, vincristine) are cheap, old and shortage-prone because thin margins push manufacturers out. A dedicated oncology line, funded by hospital consortia and philanthropy, would hold safety stock and dual-source active ingredients. The saving is not the drug price but the avoided cost of substitution, delay and dearer alternatives when a shortage hits.
Shares Prices and value, Most of the world has almost no cancer care, Platinum agents, Carboplatin.
Shares Prices and value, Most of the world has almost no cancer care, Platinum agents, Carboplatin.
Shares Prices and value, Most of the world has almost no cancer care, Carboplatin.
Shares Prices and value, Cytotoxic chemotherapy.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.